WILMINGTON, Del., Jan. 04, 2017 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Calamos Asset Management, Inc. (“Calamos Asset Management” or the “Company”) relating to the sale of the Company to an entity owned by founder John Calamos, who currently owns and controls over 77% of Calamos Asset Management’s stock. On December 19, 2016, the two parties announced that they reached an agreement in principle pursuant to which John Calamos will acquire Calamos Asset Management in a going private merger via a tender offer. As a result of the merger, Calamos Asset Management shareholders are only anticipated to receive $8.25 per share in cash in exchange for each share of Calamos Asset Management.
Andrews & Springer’s investigation so far has revealed that the consideration Calamos Asset Management shareholders are expected to receive is inadequate. While the Company claims that shareholders will receive a premium for their shares, the deal consideration is less than the average $8.95 per share price that John Calamos and his affiliates paid when they repurchased over 525,000 shares of Class A stock during the third quarter of 2016. Our investigation has also revealed that the process leading up to the announcement of the merger appears to have significant conflicts of interest thus making the process and consideration unfair.
If you own shares of Calamos Asset Management and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/calamos-asset-management-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Toll Free: 1-800-423-6013


Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



